Barry Canton - 07 Apr 2026 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Reporting relationship: 10%+ Owner
Issuer ticker: DNA
Reported as of: 07 Apr 2026
Net transaction value: -$175,067
SEC form: 4
Accepted by SEC: 10 Apr 2026, 17:01:54 UTC
Prior SEC filing: 29 Apr 2024
Next SEC filing: 13 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Karen Tepichin, Attorney-in-Fact

Key filing fact

Barry Canton filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 10 Apr 2026.

Key facts

This page summarizes Barry Canton's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
6 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Apr 2026, 17:01.

Change

Previous filing in this sequence was filed on 29 Apr 2024.
Current net transaction value: -$175,067.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001882756 Primary reporting owner

Canton Barry

Relationship: 10%+ Owner
Address: C/O GINKGO BIOWORKS HOLDINGS, 27 DRYDOCK AVENUE, BOSTON
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Signature date: 10 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +27,738
Change %: +9%
Price
Shares after: 337,101
Date: 07 Apr 2026
Ownership: Direct
Footnotes: F1

DNA transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +27,738
Change %: +8.2%
Price
Shares after: 364,839
Date: 08 Apr 2026
Ownership: Direct
Footnotes: F1

DNA transaction

Class A Common Stock

Sale

Transaction value: $91,164
Shares: -13,155
Change %: -3.6%
Price: $6.93
Shares after: 351,684
Date: 08 Apr 2026
Ownership: Direct
Footnotes: F2

DNA transaction

Class A Common Stock

Sale

Transaction value: $83,903
Shares: -13,116
Change %: -3.7%
Price: $6.40
Shares after: 338,568
Date: 09 Apr 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DNA transaction Derivative

Performance-Based Restricted Stock Unit

Options Exercise

Transaction value
Shares: -27,738
Change %: -50%
Price
Shares after: 27,738
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 27,738
Exercise price
Footnotes: F1, F3

DNA transaction Derivative

Performance-Based Restricted Stock Unit

Options Exercise

Transaction value
Shares: -27,738
Change %: -100%
Price
Shares after: 0
Date: 08 Apr 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 27,738
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each performance-based restricted stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Footnote F2

Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

Footnote F3

On June 19, 2025, the Reporting Person was granted 82,800 PSUs based on a company-wide cash flow reduction target over a one-year period beginning on January 1, 2025 and ending on December 31, 2025. The total number of vested PSUs distributed by Issuer on April 7, 2026 and April 8, 2026 in the form of Class A Common Stock reflects actual performance equal to 67% of target performance, as certified by the Compensation Committee of the Board of Directors.